



Novozymes A/S & Chr. Hansen Holding A/S Creating a Leading Global Biosolutions Partner



December 12, 2022

THIS PRESENTATION IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, AUSTRALIA AND JAPAN OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION OR WHERE SUCH ACTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, FILINGS OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED UNDER DANISH LAW.

This presentation is for informational purposes only and does not constitute a notice to an extraordinary general meeting resolving on the Merger, an exemption document or a merger prospectus and as such, does not constitute or form part of and should not be construed as, an offer to sell, or the solicitation or invitation of any offer to buy, acquire or subscribe for, any securities or any other financial instruments in Novozymes or Chr. Hansen or an inducement to enter into investment activity. Any decision with respect to the proposed statutory merger of Chr. Hansen into Novozymes should be made solely on the basis of information to be contained in the actual notices to the extraordinary general meetings of Novozymes and Chr. Hansen, as applicable, and the exemption document or merger prospectus, as applicable, related to the Merger as well as on an independent analysis of the information contained therein. Investors should consult the exemption document, when published, for more complete information about Novozymes, Chr. Hansen, their respective subsidiaries, their respective securities and the Merger.

NO OFFERING IS BEING MADE TO ANY PERSON IN ANY JURISDICTION. THIS PRESENTATION MAY NOT BE USED FOR, OR IN CONNECTION WITH, AND DOES NOT CONSTITUTE, OR FORM PART OF, AN OFFER BY, OR INVITATION BY OR ON BEHALF OF, NOVOZYMES, CHR. HANSEN, OR ANY REPRESENTATIVE OF NOVOZYMES, OR CHR. HANSEN, TO PURCHASE ANY SECURITIES OR AN OFFER TO SELL OR ISSUE, OR THE SOLICITATION TO BUY SECURITIES BY ANY PERSON IN ANY JURISDICTION. NO ACTION HAS BEEN OR WILL BE TAKEN IN ANY JURISDICTION BY NOVOZYMES OR CHR. HANSEN THAT WOULD PERMIT AN OFFERING OF THE ORDINARY SHARES OR POSSESSION OR DISTRIBUTION OF A PROSPECTUS IN ANY JURISDICTION, EXCEPT TO THE EXTENT EXPLICITLY DISCLOSED BY NOVOZYMES OR CHR. HANSEN.

This presentation is for information purposes only it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Novozymes and Chr. Hansen do not guarantee its accuracy or completeness and Novozymes and Chr. Hansen will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this presentation may be regarded as creating any right or obligation and Novozymes and Chr. Hansen expressly disclaim liability for any errors or omissions. The price and value of securities and any income from them can go down as well as up and investors could lose their entire investment. Past performance is not a guide to future performance. Information in this presentation cannot be relied upon as a guide to future performance.

This presentation is not intended to be, and shall not constitute in any way, a binding or legal agreement, or impose any legal obligation on the Novozymes Group or the Chr. Hansen Group. All proprietary rights and interest in or connected with this presentation shall vest in the Novozymes Group or the Chr. Hansen Group, as the case may be. No part of it may be redistributed or reproduced without the prior written permission of the Novozymes Group and Chr. Hansen Group. All proprietary rights and interest in or connected with this publication shall vest in Novozymes or Chr. Hansen, as the case may be. This presentation speaks only as of this date.

Additional information for US holders This presentation relates to the proposed Merger of two Danish public companies. This presentation, the exemption document and other documents relating to the proposed Merger would be prepared in accordance with European and Danish law and European and Danish disclosure requirements, format and style, all of which differ from those in the United States. The proposed Merger referred to herein and the information to be distributed in connection therewith, including the proposed Merger and related shareholder vote and any related corporate transactions, are subject to disclosure, timing and procedural requirements and practices applicable in Europe and Denmark, which differ from the disclosure requirements of the United States.

The securities referred to herein and to be issued pursuant to the proposed Merger have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act") or under any laws or with any securities regulatory authority of any state, district or other jurisdiction of the United States, and unless so registered may not be offered, pledged, sold, delivered or otherwise transferred (directly or indirectly), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state and other securities laws. There will not be any public offer of any securities in the United States. The information contained herein does not constitute an offer to sell or solicitation of an offer to buy any securities in the United States. Further details of which US holders are eligible to receive the securities referred to herein, and the procedural steps required to be taken by such persons to so receive such securities, as well as the procedures for those US holders who do not so qualify to receive such securities (if any), will be set forth in the exemption document.

Neither the U.S. Securities and Exchange Commission (SEC) nor any US state securities commission has approved or disapproved of the securities referred to herein to be issued in connection with the proposed Merger or any related corporate transaction, or determined if the information contained herein or in the exemption document to be prepared in connection with the proposed Merger is accurate or complete. Any representation to the contrary is a criminal offence in the United States.

The securities referred to herein have not been and are not presently expected to be listed on any US securities exchange or quoted on any inter-dealer quotation system in the United States. None of Novozymes or Chr. Hansen presently intends to take any action to facilitate a market in such securities in the United States.

Financial statements, and all financial information that is included in the information contained herein or that may be included in the exemption document and any other documents relating to the securities referred to herein, have been or will be prepared in accordance with International Financial Reporting Standards (IFRS) or other reporting standards or accounting practice which may not be comparable to financial statements of companies in the United States or other companies whose financial statements are prepared in accordance with generally accepted accounting principles in the United States (US GAAP).

It may be difficult for US holders to enforce their rights and claims arising out of the US federal securities laws, since Novozymes and Chr. Hansen are incorporated under the laws of Denmark and the majority or all of their respective officers and directors are residents of non-US jurisdictions. Judgments of US courts are generally not enforceable in Denmark. US holders may not be able to sue a non-US company or its officers or directors in a non-US court for violations of US securities laws. Further, it may be difficult to compel a non-US company and its affiliates to subject themselves to a US court's judgment. In addition, original actions, or actions for the enforcement of judgments of US courts, based on the civil liability provisions of the US federal securities laws, may not be enforceable in Denmark.

Each shareholder is advised to read the exemption document and is urged to consult his or her independent professional adviser regarding the tax consequences of the Merger.

Information Regarding Forward-Looking Statements. This presentation includes forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Novozymes Group's, Chr. Hansen Group's and the Combined Group's control and all of which are based on the Novozymes Group's, Chr. Hansen Group's or the Combined Group's current beliefs and expectations about future events. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as "aim", "annualized", "anticipate", "assess", "assume", "believe", "continue", "could", "estimate", "expect", "goal", "hope", "intend", "may", "objective", "plan", "position", "potential", "predict", "project", "risk", "seek", "should", "target", "will" or "would" or the highlights or the negatives thereof, other variations thereon or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this presentation and include statements that reflect the Novozymes Group's, Chr. Hansen Group's or the Combined Group's intentions, beliefs or current expectations and projections about the their respective future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, targets, strategies and opportunities and the markets in which they respectively operate, and the anticipated timing of the proposed merger. These forward-looking statements and other statements contained in this presentation regarding matters that are not historical facts involve predictions. No assurance can be given that such future results will be achieved; actual events or results may differ materially as a result of risks and uncertainties facing the Novozymes Group, Chr. Hansen Group or the Combined Group. Such risks and uncertainties could cause actual results to vary materially from the future results indicated, expressed or implied in such forward-looking statements. Forward-looking statements in this presentation speak only as of the date of this presentation. The information contained in this presentation is subject to change without notice and, except as required by applicable laws and regulations, Novozymes, and Chr. Hansen expressly disclaim any obligation or undertaking to update or revise the forward-looking statements contained in this presentation to reflect any change in its expectations or any change in events, conditions or circumstances on which such statements are based and nor does it intend to. Investors should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual future events or otherwise.

Financial Information. Financial objectives are internal objectives of Novozymes, Chr. Hansen and the Combined Group to measure its operational performance and should not be read as indicating that Novozymes, Chr. Hansen or the Combined Group is targeting such metrics for any particular financial year. The ability of Novozymes, Chr. Hansen and the Combined Group to achieve these financial objectives is inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond the control of Novozymes, Chr. Hansen and the Combined Group, and upon assumptions with respect to future business decisions that are subject to change. As a result, the actual results of Novozymes, Chr. Hansen and the Combined Group may vary from these financial objectives, and those variations may be material.

Transaction conditions. Completion of the Merger is subject to the satisfaction of a number of conditions as more fully described in this presentation. Consequently, there can be no certainty that completion of the Merger will be forthcoming.

Novozymes refers to Novozymes A/S and the Novozymes Group refers to Novozymes and its subsidiaries. Chr. Hansen refers to Chr. Hansen Holding A/S and the Chr. Hansen Group refers to Chr. Hansen and its subsidiaries. The Combined Group refers to Novozymes and its subsidiaries following completion of the Merger (including the Novozymes Group and Chr. Hansen Group).

Today's speakers



Ester Baiget
President and CEO




Mauricio Graber
President and CEO



Lars Green
Executive Vice President and
CFO



A leading global biosolutions partner to generate significant value for all stakeholders



¹Novozymes and Chr. Hansen filings, internal analysis.

²Combined financials are based on Chr. Hansen's audited Annual Report 2021/22 and Novozymes' interim reports for 9M 2022 and Q4 2021. The interim reports are not audited or reviewed. Novozymes figures converted from DKK to EUR using a single FX rate of 7.4394 (average rate October 2021 - September 2022) for purposes of translation only; CAGR reflects 2023 base year; Expectation reflects each individual company's previously

communicated targets adding synergies from the combination. Note all expectations assume constant currencies, no additional acquisitions, no divestments, no special items, a gradual normalization of the global economy. Estimated integration costs of EUR 250 million, of which approximately EUR 50 million would be capitalized, are expected through 2026. EBIT excludes integration costs and PPA amortization.

³Based on closing share prices of Novozymes B-shares of DKK 431.00 and Chr. Hansen shares of DKK 444.20, as of December 9, 2022.

~EUR15 billion market for biological solutions with potential for significant future economic impact

Global megatrends

Increasing pressures on natural resources

Increasing demand for natural, sustainable food & health solutions

Need to produce more with less

Current addressable market for biological solutions estimated at

~ **EUR 15bn**¹

Economic impact from biological solutions is expected to grow

3x
by 2040²

Customer demands

Enhancing profitability



Winning consumers

Meeting increasingly demanding regulations

Being a good corporate citizen

Global megatrends and customer demands require best-in-class scalable, efficient and sustainable biosolutions

Two leading biosolutions companies with a shared purpose and powerful capabilities will be even better together



¹Novozymes Annual Report 2021.

²Chr. Hansen Annual Report 2021/22.


Chr. Hansen business snapshot

Leading natural biosciences player with ~EUR 1.2bn in 12M trailing revenue and ~27% EBIT margins b.s.i.¹

Business highlights

- ✓ One of the world's largest commercial bacteria collections of ~40,000 strains²
- ✓ Centralized R&D and production set-up with a comprehensive network of application centers supporting sales to more than 140 countries³
- ✓ Invests ~8% of revenue into R&D⁴
- ✓ Growing portfolio of intellectual property comprising 3,400 patents and 3,100 trademarks³

12M trailing revenue breakdown (EUR 1.2bn)¹



Portfolio overview

Solutions



Microbials
(Cultures, Probiotics)



Enzymes

Lighthouses

Bacteria, Fermented Plant Bases, Bioprotection, HMO, Plant Health

¹ Chr. Hansen Annual Report 2021/22 and internal estimates; represents EBIT margin before special items.

² Chr. Hansen company website <https://www.chr-hansen.com/en/plant-health/production>.

³ Chr. Hansen Annual Report 2021/22.

⁴ Chr. Hansen Annual Report 2020/21.


Novozymes business snapshot

Leading biosolutions player with ~EUR 2.3bn in 12M trailing revenue and ~26% EBIT margins¹

Business highlights


- ✓ World's largest producer of fermented proteins, with unique ability to scale production²
- ✓ High diversified base of 2,000 customers across 30 industries and 140 countries³
- ✓ Invests 11-12% of revenue into R&D projects for new product innovation and productivity improvements⁴ providing a strong pipeline of new solutions
- ✓ Second-to-none innovation capabilities with +6,500 patents⁵

12M trailing revenue breakdown (EUR 2.3bn)¹



Portfolio overview


Solutions



Expand & Explore Areas

BioHealth, Human Nutrition, Advanced Protein Solutions, Explore Ventures (carbon capture, renewable plastics, fertilizer replacement and biocontrol)

Novozymes and Chr. Hansen creates a global biosolutions partner with a broad technology platform



Complementary strengths of each business will be better together

With a **diversified portfolio**, we expect to be even **better positioned to serve key societal needs** and leverage **future growth opportunities**



Customer-centric global reach aligned with **strong innovation capabilities** and **optimized commercialization**




NewCo¹
A leading global biosolutions partner

Capitalise on **scale, megatrends** and **customer demands** to **unlock future market opportunities**



Strong purpose-driven culture with ESG commitments, inspiring **talented employees around the world** with a track record for innovation and delivery



With a diverse portfolio across growing markets, NewCo will be even better positioned to serve key societal needs

	HEALTHIER LIVES & BETTER FOODS ~50% ^{1,2}				REDUCE CHEMICALS & CLIMATE NEUTRAL ~50% ^{1,2}			
✓ = Novozymes ✓ = Chr. Hansen	Dairy	Food & Beverages	Dietary supplements	Specialized nutrients	Household Care	BioEnergy	Agriculture, Animal Health & Nutrition	Grain & Tech processing
Enzymes	✓ ✓	✓	✓	✓	✓	✓	✓	✓
Microbials	✓	✓ ✓	✓ ✓	✓	✓	✓	✓ ✓	✓
Other technologies ³			✓ ✓	✓ ✓				
NewCo position ⁴	← <i>Leading</i> →							


Complementary portfolio in sectors with strong underlying growth and/or sustainability opportunities

¹ Novozymes and Chr. Hansen company filings, internal estimates; Reflects proportion of combined NewCo FY2021A revenue.

³ For example, alternative proteins.

² Novozymes and Chr. Hansen are complementary, with different technologies and solutions and play in different parts of the value chain in the areas where the companies are both indicated to have activities ⁴ Across enzymes, microbials and proteins.

Customer-centric global reach aligned with innovation capabilities from 38 R&D and application centers and 23 manufacturing sites¹



Capitalize on megatrends, customer demands and scale to unlock the opportunities of the future

Combining core technologies in **essential components**...



... focusing on key global **megatrends**....



... addressing **customers' evolving demand** for biosolutions



Accelerated growth ambitions and balanced industry exposure across fast growing markets

Example: Plant-based yoghurt "from farm to spoon"

Microbes Enzymes Proteins

GROW



Increase plant yield and reduce chemicals

EXTRACT/ENHANCE



Protein extraction with enhanced texture and flavour

FERMENT



Fermentation and strong process control


ENRICH



Enrichment with high-value proteins


Example: Human Health

UNDERSTAND & EVIDENCE




Enzyme, microbe and protein libraries plus deep understanding of microbiome science

CREATE




Developing solutions with advanced AI-based screening.

SCALE



World-leading scaled fermentation technologies

REACH



Leverage multiple channels to market and global presence

Strong purpose-driven culture with clear ESG commitments backed by global talent

Strong purpose-driven culture – built on complementary values and shared Danish heritage, inspired by the power of biosolutions



~10,000 talented, passionate and diverse people – attracting, retaining and developing the top innovators in our sector



Sustainability as an integral part of strategies

Global recognitions



Committed to a healthy planet and sustainable future, joining with global partners to lead the way

ESG commitments




Cost and revenue synergies drive significant near-term value creation

Overview of synergies

		<u>% Share (cost)</u>
COGS	<ul style="list-style-type: none"> • Production optimisation • Repair and maintenance and consumables efficiencies • Procurement savings from contract bundling and logistics footprint optimisation 	~40 - 50% (of total)
SG&A	<ul style="list-style-type: none"> • Rationalisation of third party contractors and management overlap across functions • Selling and admin overheads 	~50 - 60% (of total)
Revenue	<ul style="list-style-type: none"> • Leveraging commercial excellence to cross-sell joint product offerings in expanded market • Combining individual strengths in product technology and sales channels in food and beverage • Acceleration of technology penetration into dietary supplements in human health • Acceleration of probiotics sales in animal health and Bioagriculture 	

Run-rate EBIT contribution



Integration Costs

- Estimated EUR 250 million expected through 2026, of which approximately EUR 50 million would be capitalized¹

Phasing

- Estimated run-rate cost synergies achieved by year 3; run-rate revenue synergies achieved by year 4

Strong sustainable growth levels from a solid underlying business combined with new accelerating growth opportunities

3. Strategically positioned to realise the future demand for biosolutions

Healthier lives & better foods

Reduce chemicals & climate neutral

2. Accelerated opportunities leveraging each company's core strengths

Scientific capabilities

Market access


Scale-up capacity

1. Growth from revenue synergies

Cross selling opportunities

Innovation efficiencies

Accelerated long-term organic revenue growth*



Scale, Optimize, Innovate, Commercialize

NewCo to have an attractive financial profile and meaningful scale

Combined Financials (Trailing 12M Reported Financials)^{1,2}

<i>EUR billion</i>	Novozymes Oct 2021 - Sep 2022	Chr. Hansen Sep 2021 - Aug 2022	NewCo (excl. PPA amortization)	Synergies³	NewCo incl. synergies (excl. PPA amortization)
Revenue	2.3	1.2	3.5	0.20	3.7
EBITDA	0.8	0.4	1.2	0.16-0.18	1.4
EBITDA margin %	34%	35%	35%		37%
EBIT	0.6	0.3	0.9	0.16-0.18	1.1
EBIT margin %	26%	26%	26%		29%

17 ¹ Combined financials are without adjustments of accounting principles and eliminations. The compiled financial have not been audited or reviewed by an external auditor.

² Combined financials are based on Chr. Hansen's audited Annual Report 2021/22 and Novozymes' unaudited interim reports for 9M 2022 and Q4 2021. Novozymes figures converted from DKK to EUR using a single FX rate of 7.4394 (average rate October 2021 – September 2022) for purposes of translation only.

³ Figures represent run-rate synergies in 2027 provided completion of merger within expected time frame.

NewCo financial expectations and sustainability ambitions are best-in-class

Financial

Organic revenue growth CAGR¹: 6-8% until 2025 including synergies

EBIT² margin: 29% by 2025 excluding integration costs and PPA amortization

Earnings Per Share³: Mid-single digit percentage accretive in third year after completion

Financial Policy

Balance sheet: No additional debt is expected to be issued as a result of the transaction; expected leverage (NIBD/EBITDA) at completion 1.3-1.7x, which is also the expected future net debt level

Dividend: Expected ~50% payout ratio following completion

Sustainability

Emissions⁴: Carbon neutrality by 2050; 75% reduction in absolute CO2 emissions from operations (Scopes 1+2) and 35% reduction in absolute CO2 emissions from supply chain (Scope 3) by 2030

People⁵: Minimum, 45% women and 45% men across all professionals and senior management by 2030

Transaction Summary


<p>Transaction Consideration</p>	<p>Chr. Hansen Free Float¹:</p> <ul style="list-style-type: none"> 1.5326x Novozymes B-shares per Chr. Hansen share 49% premium to Chr. Hansen's closing share price² as of 09-Dec-22 	<p>Novo Holdings:</p> <ul style="list-style-type: none"> 1.0227x Novozymes B-shares per Chr. Hansen share
<p>Blended Premium</p>	<ul style="list-style-type: none"> Blended exchange ratio of 1.4205x with implied blended premium paid of 38% 	
<p>Economic Ownership</p>	<ul style="list-style-type: none"> After completion of the Merger, Novozymes free float shareholders to own in aggregate 44%, Chr. Hansen free float shareholders to own in aggregate 34% and Novo Holdings to own in aggregate 22% of the share capital of the combined group³ 	
<p>Dividends</p>	<ul style="list-style-type: none"> Each of Novozymes and Chr. Hansen intends, subject to applicable law, to distribute dividends in the ordinary course and may effect certain extraordinary dividends prior to completion, in each case in line with the principles of each of Novozymes' and Chr. Hansen's existing dividend policy. 	
<p>Novo Holdings Commitments</p>	<ul style="list-style-type: none"> Irrevocable undertaking to exchange its current approximately 22% stake in Chr. Hansen at an exchange ratio of 1.0227 new B-Shares in Novozymes (each with a nominal value of DKK 2) for each individual Chr. Hansen share Undertaking to vote on its shares in Novozymes and Chr. Hansen in favor of the transaction at Novozymes' and Chr. Hansen's respective EGMs Novo Holdings firmly intends to maintain approximately 25.5% ownership of the total share capital of the combined group through incremental cash investment, contemplated via purchases of existing shares. 	
<p>Transaction Structure</p>	<ul style="list-style-type: none"> Statutory merger between Novozymes and Chr. Hansen with Novozymes as the continuing entity and Chr. Hansen as the dissolving entity The merger must be approved at EGMs in each of Chr. Hansen and Novozymes (requires 2/3 majority of votes and shares present at the EGMs) 	
<p>Capital Allocation</p>	<ul style="list-style-type: none"> No additional debt is expected to be issued as a result of the transaction, and the leverage (NIBD/EBITDA) at completion is expected at 1.3-1.7x, which is also the expected future net debt level. Expected ~50% payout ratio following completion 	
<p>Key Conditions</p>	<ul style="list-style-type: none"> Completion of the merger is subject to, inter alia, approval by EGMs of Novozymes and Chr. Hansen respectively as well as customary merger control and other regulatory approvals from relevant authorities 	
<p>Transaction Timing</p>	<ul style="list-style-type: none"> Danish exemption document expected to be published in H1 2023 prior to the EGMs EGMs of Novozymes and Chr. Hansen expected to be held in H1 2023 The merger is expected to be completed in Q4, calendar year 2023 or Q1, calendar year 2024 	

¹Shares held by Chr. Hansen shareholders, other than Novo Holdings' current ownership of 28,983,112 Chr. Hansen shares as of December 9, 2022.

²As quoted on the Nasdaq Copenhagen.

³Excludes impact of any potential future share purchases made by Novo Holdings. Inclusive of Novozymes treasury shares.

Indicative timeline and key milestones



NewCo governance and management to have representation and best talent from both Novozymes and Chr. Hansen

NewCo Board of Directors			Other				
<p>Chair</p> <p>Novozymes</p>	<p>Vice Chair</p> <p>Chr. Hansen</p>	<p>Board Members (excl. Chairs)</p> <table border="0"> <tr> <td>Novo Holdings x2</td> <td>Chr. Hansen x2</td> </tr> <tr> <td>Novozymes x2</td> <td>Employees x4 Novozymes x2 observers Chr. Hansen</td> </tr> </table>	Novo Holdings x2	Chr. Hansen x2	Novozymes x2	Employees x4 Novozymes x2 observers Chr. Hansen	<p>NewCo Name: TBD</p> <p>Headquarters: Denmark – exact location TBD</p> <p>Fiscal Year End: 31-Dec</p>
Novo Holdings x2	Chr. Hansen x2						
Novozymes x2	Employees x4 Novozymes x2 observers Chr. Hansen						
NewCo Executive Committee							
<p>CEO</p> <p>Ester Baiget Novozymes</p>		<p>CFO</p> <p>Lars Green Novozymes</p>					

Novo Holdings fully supports the proposed combination of the two companies

“The two companies are a perfect match. Chr. Hansen with its expertise in microbials and Novozymes with its background in enzymes. Combining the two companies will create a global leader in biosolutions.”

- Lars Rebien Sørensen, Chairman of Novo Holdings A/S and Novo Nordisk Fonden¹

“As long-term shareholders in both Novozymes and Chr. Hansen, we are in full support of the plans to combine the two companies. Due to our strong belief in the commercial, strategic, and long-term financial merits of this transaction, we are willing to accept a less favorable exchange ratio for our shares in Chr. Hansen than what is offered to other shareholders.”

- Kasim Kutay, CEO of Novo Holdings A/S¹

A 'better together' gamechanger – with increased value creation opportunity

Complementary strengths of each business leveraged to create a **leading global biosolutions partner** with broad biological toolbox


Global megatrends and industry tailwinds support 'stronger together' rationale

Strong innovation capabilities unlock significant growth opportunities and strengthens combined group

Purpose-driven culture and complementary values with **clear ESG commitments and shared Danish heritage**

Attractive financial profile, with strong revenue growth and attractive margins

Accelerated, sustainable, and derisked innovation and organic revenue growth from near-term initiatives and the development of new opportunities



Q&A



Appendix



DKK - NewCo to have an attractive financial profile and meaningful scale

DKK - Combined Financials (Trailing 12M Reported Financials)^{1,2}

<i>DKK billion</i> <i>(DKK/EUR of 7.4394)</i>	Novozymes Oct 2021 - Sep 2022	Chr. Hansen Sep 2021 - Aug 2022	NewCo (excl. PPA amortization)	Synergies³	NewCo incl. synergies (excl. PPA amortization)
Revenue	16.9	9.0	25.9	1.5	27.4
EBITDA	5.8	3.2	9.0	1.2-1.3	10.3
EBITDA margin %	34%	35%	35%		37%
EBIT	4.3	2.4	6.7	1.2-1.3	8.0
EBIT margin %	26%	26%	26%		29%

¹ Combined financials are without adjustments of accounting principles and eliminations. The compiled financial have not been audited or reviewed by an external auditor.

² Combined financials are based on Chr. Hansen audited Annual Report 2021/22 and Novozymes interim reports for 9M 2022 and 12M 2021. The interim reports are not audited or reviewed. Chr. Hansen figures converted from EUR to DKK using a single FX rate of 7.4394 (average rate September 2021 - August 2022) for purposes of translation only.

³ Figures represent run-rate synergies in 2027.